Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ascorbic Acid | 6 | 2008 | 23 | 0.550 |
Why?
|
| Vasculitis | 2 | 2014 | 7 | 0.490 |
Why?
|
| Protein Disulfide-Isomerases | 2 | 2013 | 4 | 0.490 |
Why?
|
| Macrophage-1 Antigen | 2 | 2014 | 5 | 0.410 |
Why?
|
| Neutrophil Infiltration | 1 | 2013 | 2 | 0.390 |
Why?
|
| Mice | 14 | 2017 | 465 | 0.330 |
Why?
|
| Melanoma, Experimental | 2 | 2007 | 4 | 0.320 |
Why?
|
| Animals | 15 | 2017 | 1349 | 0.300 |
Why?
|
| Cell Cycle | 2 | 2009 | 6 | 0.290 |
Why?
|
| Reactive Oxygen Species | 6 | 2009 | 36 | 0.260 |
Why?
|
| Apoptosis | 10 | 2009 | 65 | 0.230 |
Why?
|
| Neutrophils | 3 | 2014 | 31 | 0.220 |
Why?
|
| Cell Proliferation | 3 | 2008 | 43 | 0.200 |
Why?
|
| Signal Transduction | 7 | 2009 | 139 | 0.180 |
Why?
|
| Blood Platelets | 2 | 2013 | 19 | 0.180 |
Why?
|
| Interleukin-18 | 3 | 2004 | 7 | 0.150 |
Why?
|
| Mice, Knockout | 3 | 2014 | 103 | 0.140 |
Why?
|
| Humans | 13 | 2017 | 5837 | 0.140 |
Why?
|
| Melanoma | 3 | 2008 | 16 | 0.140 |
Why?
|
| Prostatic Neoplasms | 2 | 2009 | 13 | 0.140 |
Why?
|
| Mitochondria | 3 | 2009 | 19 | 0.130 |
Why?
|
| Apolipoproteins | 1 | 2017 | 3 | 0.130 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2017 | 5 | 0.130 |
Why?
|
| Lipoproteins, HDL | 1 | 2017 | 5 | 0.130 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2017 | 7 | 0.130 |
Why?
|
| Podocytes | 1 | 2017 | 8 | 0.130 |
Why?
|
| Proteinuria | 1 | 2017 | 8 | 0.130 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2017 | 12 | 0.130 |
Why?
|
| Male | 6 | 2017 | 3399 | 0.120 |
Why?
|
| Cells, Cultured | 3 | 2013 | 167 | 0.120 |
Why?
|
| NF-kappa B | 2 | 2005 | 27 | 0.110 |
Why?
|
| Caspases | 3 | 2007 | 12 | 0.110 |
Why?
|
| Protein Binding | 2 | 2013 | 43 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 2 | 2005 | 12 | 0.110 |
Why?
|
| Transcription Factor AP-1 | 2 | 2005 | 7 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 17 | 0.100 |
Why?
|
| Hemostasis | 1 | 2013 | 3 | 0.100 |
Why?
|
| Blood Vessels | 1 | 2013 | 4 | 0.100 |
Why?
|
| Extracellular Space | 1 | 2013 | 6 | 0.100 |
Why?
|
| Ligands | 1 | 2013 | 13 | 0.100 |
Why?
|
| Cell Adhesion | 1 | 2013 | 12 | 0.100 |
Why?
|
| Thrombosis | 1 | 2013 | 16 | 0.100 |
Why?
|
| Inflammation | 1 | 2013 | 53 | 0.090 |
Why?
|
| Cell Line, Tumor | 6 | 2009 | 63 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2007 | 110 | 0.090 |
Why?
|
| Rats | 1 | 2013 | 282 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 2 | 2008 | 12 | 0.080 |
Why?
|
| Embryonic Stem Cells | 1 | 2011 | 4 | 0.080 |
Why?
|
| fas Receptor | 2 | 2007 | 4 | 0.080 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 3 | 0.070 |
Why?
|
| Thiocyanates | 1 | 2009 | 4 | 0.070 |
Why?
|
| Membrane Glycoproteins | 2 | 2013 | 18 | 0.070 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2008 | 7 | 0.070 |
Why?
|
| Antioxidants | 2 | 2005 | 22 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2005 | 32 | 0.070 |
Why?
|
| Skin Neoplasms | 2 | 2005 | 19 | 0.070 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2007 | 3 | 0.070 |
Why?
|
| G1 Phase | 1 | 2007 | 6 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2007 | 8 | 0.070 |
Why?
|
| Burkitt Lymphoma | 1 | 2007 | 2 | 0.070 |
Why?
|
| Fas Ligand Protein | 1 | 2007 | 4 | 0.070 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2007 | 5 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2007 | 27 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2005 | 31 | 0.060 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2007 | 3 | 0.060 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2007 | 9 | 0.060 |
Why?
|
| Insulin | 1 | 2007 | 16 | 0.060 |
Why?
|
| Liver | 1 | 2007 | 22 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2007 | 30 | 0.060 |
Why?
|
| Allyl Compounds | 1 | 2006 | 2 | 0.060 |
Why?
|
| Sulfides | 1 | 2006 | 2 | 0.060 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2006 | 3 | 0.060 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2006 | 3 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 27 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2014 | 122 | 0.060 |
Why?
|
| Oleanolic Acid | 1 | 2005 | 4 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2005 | 6 | 0.060 |
Why?
|
| Osteoclasts | 1 | 2005 | 9 | 0.060 |
Why?
|
| Receptors, Transferrin | 1 | 2005 | 2 | 0.060 |
Why?
|
| Iron | 1 | 2005 | 6 | 0.060 |
Why?
|
| Arsenicals | 1 | 2005 | 5 | 0.060 |
Why?
|
| Oxides | 1 | 2005 | 5 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 8 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2005 | 3 | 0.060 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2004 | 3 | 0.060 |
Why?
|
| Microglia | 1 | 2004 | 25 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2004 | 6 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2004 | 10 | 0.050 |
Why?
|
| RNA, Messenger | 4 | 2007 | 87 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 66 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 22 | 0.050 |
Why?
|
| Keratinocytes | 1 | 2002 | 2 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2002 | 7 | 0.050 |
Why?
|
| Antigens, Surface | 1 | 2002 | 4 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 2006 | 31 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2013 | 48 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2011 | 32 | 0.030 |
Why?
|
| Apolipoprotein L1 | 1 | 2017 | 3 | 0.030 |
Why?
|
| Surface Plasmon Resonance | 1 | 2017 | 3 | 0.030 |
Why?
|
| Alleles | 1 | 2017 | 89 | 0.030 |
Why?
|
| Genotype | 1 | 2017 | 114 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2008 | 36 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 123 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2008 | 17 | 0.030 |
Why?
|
| Pyridines | 2 | 2008 | 13 | 0.030 |
Why?
|
| Imidazoles | 2 | 2008 | 21 | 0.030 |
Why?
|
| Enzyme Inhibitors | 2 | 2008 | 51 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 406 | 0.030 |
Why?
|
| Young Adult | 1 | 2017 | 421 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 37 | 0.030 |
Why?
|
| Adolescent | 1 | 2017 | 488 | 0.030 |
Why?
|
| Cell Survival | 2 | 2005 | 31 | 0.030 |
Why?
|
| HL-60 Cells | 2 | 2005 | 6 | 0.030 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2005 | 8 | 0.030 |
Why?
|
| Talin | 1 | 2014 | 2 | 0.030 |
Why?
|
| Platelet Aggregation | 1 | 2014 | 3 | 0.030 |
Why?
|
| Anemia, Sickle Cell | 1 | 2014 | 6 | 0.030 |
Why?
|
| Cell Communication | 1 | 2014 | 10 | 0.030 |
Why?
|
| Fibrin | 1 | 2013 | 3 | 0.020 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2013 | 3 | 0.020 |
Why?
|
| Shear Strength | 1 | 2013 | 6 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2013 | 12 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2013 | 52 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2014 | 80 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2013 | 16 | 0.020 |
Why?
|
| Caspase 8 | 2 | 2003 | 4 | 0.020 |
Why?
|
| Caspase 9 | 2 | 2003 | 4 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 222 | 0.020 |
Why?
|
| Adult | 1 | 2017 | 1670 | 0.020 |
Why?
|
| Middle Aged | 1 | 2017 | 1775 | 0.020 |
Why?
|
| Aged | 1 | 2017 | 1860 | 0.020 |
Why?
|
| Calcium | 1 | 2013 | 244 | 0.020 |
Why?
|
| Pseudopodia | 1 | 2011 | 2 | 0.020 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2011 | 2 | 0.020 |
Why?
|
| Microcirculation | 1 | 2011 | 13 | 0.020 |
Why?
|
| Platelet Transfusion | 1 | 2011 | 3 | 0.020 |
Why?
|
| Megakaryocytes | 1 | 2011 | 21 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2011 | 46 | 0.020 |
Why?
|
| Female | 1 | 2017 | 3346 | 0.020 |
Why?
|
| Electron Transport | 1 | 2009 | 3 | 0.020 |
Why?
|
| Sulfoxides | 1 | 2009 | 3 | 0.020 |
Why?
|
| Isothiocyanates | 1 | 2009 | 3 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2009 | 4 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2009 | 8 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2009 | 4 | 0.020 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2009 | 3 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2009 | 17 | 0.020 |
Why?
|
| Vitamins | 1 | 2008 | 5 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 17 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2008 | 9 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2007 | 3 | 0.020 |
Why?
|
| Mice, Obese | 1 | 2007 | 3 | 0.020 |
Why?
|
| Gluconeogenesis | 1 | 2007 | 3 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2006 | 8 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2006 | 7 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 13 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2006 | 21 | 0.020 |
Why?
|
| Cell Movement | 1 | 2006 | 24 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2006 | 48 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2005 | 9 | 0.010 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2005 | 2 | 0.010 |
Why?
|
| I-kappa B Kinase | 1 | 2005 | 2 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 4 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2005 | 3 | 0.010 |
Why?
|
| Protein Transport | 1 | 2005 | 7 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 2005 | 12 | 0.010 |
Why?
|
| Glutathione | 1 | 2005 | 9 | 0.010 |
Why?
|
| DNA | 1 | 2005 | 38 | 0.010 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2004 | 2 | 0.010 |
Why?
|
| Titrimetry | 1 | 2004 | 3 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2004 | 12 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2005 | 38 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2004 | 9 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2004 | 8 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 44 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2004 | 14 | 0.010 |
Why?
|
| Densitometry | 1 | 2003 | 2 | 0.010 |
Why?
|
| Acetylcysteine | 1 | 2003 | 3 | 0.010 |
Why?
|
| Immunoprecipitation | 1 | 2003 | 5 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 35 | 0.010 |
Why?
|
| Cytochromes c | 1 | 2003 | 2 | 0.010 |
Why?
|
| Oxidants | 1 | 2003 | 7 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2003 | 106 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2002 | 4 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 75 | 0.010 |
Why?
|
| Cell Line | 1 | 2002 | 72 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 374 | 0.010 |
Why?
|
| CD48 Antigen | 1 | 2002 | 2 | 0.010 |
Why?
|
| Palatine Tonsil | 1 | 2002 | 2 | 0.010 |
Why?
|
| Trihexosylceramides | 1 | 2002 | 2 | 0.010 |
Why?
|
| Neprilysin | 1 | 2002 | 2 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 2002 | 2 | 0.010 |
Why?
|
| CD40 Antigens | 1 | 2002 | 2 | 0.010 |
Why?
|
| CD40 Ligand | 1 | 2002 | 2 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2002 | 2 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2002 | 4 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2002 | 54 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2002 | 12 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2002 | 23 | 0.010 |
Why?
|